Novo Nordisk (NVO) Stock Overview
Engages in the research and development, manufacture, and distribution of pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
NVO Community Fair Values
Create NarrativeSee what 655 others think this stock is worth. Follow their fair value or set your own to get alerts.
Top Community Narratives
Novo Nordisk A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 43.75 |
| 52 Week High | DKK 81.44 |
| 52 Week Low | DKK 35.12 |
| Beta | 0.35 |
| 1 Month Change | -2.50% |
| 3 Month Change | 13.40% |
| 1 Year Change | -39.78% |
| 3 Year Change | -45.12% |
| 5 Year Change | 3.23% |
| Change since IPO | 24,038.06% |
Recent News & Updates
Recent updates
Seeking Alpha • Jun 03
Novo Nordisk: Deeply Undervalued With A Return To Growth In 2027
Summary Novo Nordisk is rated a strong buy, offering a 4.2% yield and trading at a 40% discount to fair value. NVO’s growth is temporarily pressured by U.S. price cuts and competition, but volume and product expansion position it for double-digit growth from 2027 onward. The Wegovy franchise, including a high-performing pill, is outpacing competitors internationally, with robust pipeline milestones expected in 2026–2027. Dividend growth is expected to average 7.5% through 2030, and total return CAGR is estimated at 18–23% over five years. Read the full article on Seeking Alpha
New Narrative • May 04
One of the two dominant players in a market projected to double, and possibly triple, over the next 5 to 8 years.
Catalysts Recent success in a phase IIIa trial showed once-daily doses of oral semaglutide demonstrated a statistically significant and superior reduction in HbA1c by 0.83% versus placebo at 26 weeks for adolescents with Type II diabetes. Based on the study data, NVO intends to seek regulatory approval for oral semaglutide in adolescents aged 10 to 17 with T2D for both Rybelsus and oral Ozempic in the U.S. and the EU in the second half of the year.Narrative Update • Jan 06
Valuation reset, but the GLP-1 franchise (and optionality) remains intact
Novo Nordisk (NVO) has continued to face a tougher near-term backdrop, but the longer-term investment case remains intact. Management has narrowed 2025 guidance to 8–11% sales growth and 4–7% operating profit growth (constant exchange rates), explicitly citing intensifying competition and pricing pressure in both diabetes and obesity.Analysis Article • Aug 05
Weekly Picks: ASML's Selloff Explained, WH's Global Expansion, and NVO's Market Mispricing
This week’s picks cover: Why now might be an opportune time to consider ASML, How Wyndham Hotels' loyalty revenue and global expansion are driving growth, and why Novo Nordisk's risk/reward case is better than it seems.New Narrative • Aug 05
A Quality Compounder Marked Down on Overblown Fears
Policy pressure: US price cuts via the IRA and executive orderSeeking Alpha • Apr 26
Novo Nordisk: Examining Tariff And Pricing Risks
Summary Novo Nordisk has a strong balance sheet and high returns on equity, but faces challenges with its next-gen weight loss drug, CagriSema. Political risks, including potential US drug price normalization and tariffs, could impact Novo's profitability significantly. Despite competition, Novo's leadership in the weight loss drug market and growth potential make it a compelling buy at $50. With a 3.8% yield and solid EPS growth, Novo could offer attractive returns, assuming manageable political risks and continued market expansion. We consider the stock a hold at $62. Read the full article on Seeking AlphaSeeking Alpha • Apr 18
Novo Nordisk: A Price Too Low To Ignore
Summary Weight loss leader Novo Nordisk has had a poor performance at the stock markets year-to-date [YTD] even as the healthcare sector is among the least impacted ones. The key reason for this is disappointing results for its drug trials, though challenges like potential tariffs on Denmark, its home country, also play a part. Yet, the company's robust fundamentals, healthy outlook and attractive market multiples go in its favour, justifying a Buy rating. Read the full article on Seeking AlphaSeeking Alpha • Mar 30
Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors
Summary Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of drugs and product candidates relative to the rival. Dear Seeking Alpha readers, you will discover whether Novo Nordisk or Eli Lilly is a more attractive stock in the long term. Read the full article on Seeking AlphaSeeking Alpha • Mar 10
Novo Nordisk: CagriSema Disappoints Again
Summary Novo Nordisk A/S' CagriSema disappointed investors again, but today's update should not have surprised anyone. The flexible dosing protocol in the REDEFINE trials likely led to suboptimal efficacy, with only 61.9% on the highest dose in the REDEFINE-2 trial. The efficacy data to date suggest CagriSema has similar efficacy to Eli Lilly's tirzepatide, and much better efficacy than semaglutide. Novo Nordisk plans to start the REDEFINE-11 trial to improve the efficacy of CagriSema, aiming for higher weight loss that could beat tirzepatide and potentially match Eli Lilly's retatrutide. Eli Lilly may have the upper hand in the obesity market, but I expect Novo Nordisk to remain a formidable competitor, with multiple other shots on goal in the clinic. Read the full article on Seeking AlphaSeeking Alpha • Feb 20
Why Novo Nordisk Is A Strong Buy Despite Market Concerns
Summary Novo Nordisk is doing exceptionally well in the face of the challenges posed by Eli Lilly. So, sales of Ozempic and Wegovy amounted to DKK 53.7 billion in the fourth quarter of 2024, increasing by 35.4% year-on-year despite competition from Mounjaro. In addition, at the end of January 2025, Novo Nordisk published data from a phase 1b/2a clinical study with amycretin, which beat even my wildest expectations. In this article, you will learn why I believe Novo Nordisk is an attractive stock for long-term investors. Read the full article on Seeking AlphaSeeking Alpha • Feb 13
Novo Nordisk: Dips Like These Come Once Every Few Years
Summary Novo Nordisk shares have dropped significantly in December due to disappointing CagriSema trial results, but not everything from those results was negative. Amycretin's promising early-stage results and the optimistic market forecasts for GLP-1 drugs and obesity care suggest that there's lots of long-term upside potential. The stock's valuation is attractive, with a P/E ratio closer to historical levels and a forward PEG ratio under 1x, which is great for a high-quality growth company. The company still expects a good amount of growth this year, and analysts forecast earnings growth of over 20% per year for the next two years. Despite risks like competition and political headwinds, Novo Nordisk's history of recovering from dips and consistent earnings growth supports a Strong Buy rating. Read the full article on Seeking AlphaSeeking Alpha • Feb 05
Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today
Summary Novo Nordisk A/S today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn and a 26% rise in operating profit to ~$17.91bn for 2024. The company’s GLP-1 drugs, Ozempic and Wegovy, drove significant revenue growth, accounting for 61% of total sales, despite some market challenges. Insulin sales also outperformed. Novo’s next-gen candidate, CagriSema, has shown promising weight loss results, though it fell short of some expectations, impacting the stock price. Management outlined plans to submit for approval in '26. With strong 2025 guidance and potential new approvals, I rate NVO stock a “Buy” due to its dominant GLP-1 market position and growth prospects. Read the full article on Seeking AlphaShareholder Returns
| NVO | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.9% | -0.5% | -0.1% |
| 1Y | -39.8% | 40.7% | 26.3% |
Return vs Industry: NVO underperformed the US Pharmaceuticals industry which returned 40.7% over the past year.
Return vs Market: NVO underperformed the US Market which returned 26.3% over the past year.
Price Volatility
| NVO volatility | |
|---|---|
| NVO Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NVO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NVO's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 67,900 | Maziar Doustdar | www.novonordisk.com |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
Novo Nordisk A/S Fundamentals Summary
| NVO fundamental statistics | |
|---|---|
| Market cap | US$195.50b |
| Earnings (TTM) | US$18.95b |
| Revenue (TTM) | US$50.93b |
10.3x
P/E Ratio3.8x
P/S RatioIs NVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVO income statement (TTM) | |
|---|---|
| Revenue | DKK 327.80b |
| Cost of Revenue | DKK 55.09b |
| Gross Profit | DKK 272.72b |
| Other Expenses | DKK 150.76b |
| Earnings | DKK 121.96b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 05, 2026
| Earnings per share (EPS) | 27.51 |
| Gross Margin | 83.20% |
| Net Profit Margin | 37.20% |
| Debt/Equity Ratio | 67.7% |
How did NVO perform over the long term?
See historical performance and comparisonDividends
4.1%
Current Dividend Yield43%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/04 07:42 |
| End of Day Share Price | 2026/06/04 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novo Nordisk A/S is covered by 54 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Gerhard Schwarz | Baader Helvea Equity Research |
| José Romero Herrero | Banco Santander |